Cagrilintide is a copy of amylin. Amycretin is a copy of the gut hormone GLP-1.
Amylin is the fullness hormone your pancreas releases alongside insulin.
The difference is reach: Cagrilintide acts on 1 receptor and Amycretin acts on 2 receptors. More receptors has generally meant more effect, and more side effects.
| Comparison | Cagrilintide AM833 | Amycretin |
|---|---|---|
| How it works | How it works Cagrilintide copies amylin rather than GLP-1. Amylin is a separate fullness hormone your pancreas releases alongside insulin, which is why it can be combined with a GLP-1 drug instead of competing with one. | How it works Amycretin is a single molecule carrying two different fullness signals, GLP-1 and amylin. CagriSema achieves something similar by combining two drugs; this does it with one. |
| What it is | A weekly fullness-hormone shot, often paired with semaglutide for bigger loss. | An experimental two-in-one weight-loss compound, as a pill or a shot. |
| Status | In trialsInvestigational | In trialsInvestigational |
| Typical dose | 0.3–4.5 mg per dose | 0.3–60 mg per week |
| How often | Weekly | Weekly/daily |
| Stays active | ~8 days | Not established |
| Dose comes from | Clinical trial protocol | Clinical trial protocol |
| Cycled? | Not cycled in the trials Clinical trial protocol | Not cycled in the trials Clinical trial protocol |
| What it does | ||
| Drug class | Amylin analog | GLP-1 + amylin (one molecule) |
| Used for | People use it to feel full and eat less by copying a natural fullness hormone. It is often paired with semaglutide for bigger weight loss. | An experimental compound that combines two appetite-lowering effects in one, with strong early weight-loss numbers. It comes as a pill and a shot in trials. |
| Receptors hit | amylin | GLP-1, amylin |
| Numbers | ||
| Full dose line | 0.3 up to 4.5 mg per dose (start low, increase slowly) | 0.3 up to 60 mg per week (start low, increase slowly) |
| Why that cycle | Given continuously for the whole study period: 26 weeks on its own, 68 weeks as part of REDEFINE 1. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break. | Given continuously for the whole study period: 36 weeks injected, 12 weeks oral. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break. |
| Weight / effect | Not measured in a trial | Not measured in a trial |
| Chain length | Not disclosed | 68 residues |
| Common vial | 10 mg | 10 mg |
| Before you start | ||
| Route | Under the skin (subcutaneous) | By mouth or under the skin |
| Do not use if | No formal contraindications established, since it is still investigational Pregnancy Caution alongside other blood-sugar-lowering medicines | No formal contraindications established Pregnancy |
What people actually report
Cagrilintide
- Nausea and other stomach side effects are common.
- It is not approved on its own and is still increased slowly from low doses in trials.
- Severe stomach pain that spreads to your back
- Vomiting badly enough that you cannot keep fluids down
Amycretin
- Stomach side effects are expected.
- It is trial-only and not available.
- Vomiting badly enough that you cannot keep fluids down
- Severe stomach pain that spreads to your back
Side effects are what users and trials report most often, not a complete list. Anything sudden, spreading, or breathing-related is an emergency regardless of which compound caused it.
People also compare
This comparison does not cover cost, long-term safety, or how you personally will respond. Effect figures come from separate trials in different populations and are not always directly comparable to each other. Nothing here is medical advice or a recommendation to use any of these. Talk to a clinician about your own situation.